Methods Study to Evaluate Use of Cardiac Ultrasound to Assess Heart Valve Abnormality in People.

This study has been completed.

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00359489

Purpose

Methods study to evaluate use of cardiac ultrasound to assess heart valve abnormality in people.

Condition	Intervention
Heart Valve Diseases	Device: cardiac echosonography

MedlinePlus related topics: Heart Valve Diseases Ultrasound

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Defined Population, Prospective Study
Official Title:	A Randomized, Open-Label, Methodology Trial To Investigate The Utility Of Echocardiography In Assessment Of Cardiac Valvular Regurgitation In Adult Subjects

Further study details as provided by Pfizer:

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Pregnant females
Those with unstable/new onset diseases
Those who are on agents known to be associated with cardiac valvular heart disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00359489

Locations

United States, Connecticut
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511-5473

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Study ID Numbers:	A9001336
Study First Received:	July 31, 2006
Last Updated:	September 13, 2007
ClinicalTrials.gov Identifier:	NCT00359489
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Heart Diseases
Congenital Abnormalities
Heart Valve Diseases

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009